Gain announces ‘Music to Your Nose’ event
CINCINNATI — Gain detergent, a brand from Procter & Gamble, announced that it will give attendees of this year's Essence Festival a scent-filled experience with Gain flings! "Music to Your Nose," which will take place inside P&G's My Black is Beautiful booth at the Ernest N. Morial Convention Center.
Visitors will receive samples of Gain flings! and have the chance to enter to win raffle prizes, which include tickets to the Essence Festival Main Stage concerts. Also in attendance at the booth will be reality television stars the Braxton Sisters, who will take photos with fans and tweet from behind the scenes.
“There is no other musical weekend that inspires quite the same joy and excitement that Essence Festival does,” said Diana Banuelos, P&G brand manager for Gain. “This is the perfect opportunity to engage with our African-American Gainiacs and introduce them to our best Gain ever, Gain flings! laundry pacs. We’re very excited to be here.”
Gain flings! are available in both Orignal Scent and Moonlight Breeze for a suggested retail price that ranges from $4.49 for a 14-count bag to $21.49 for a 90-count tub.
FDA seeks public comment regarding four-year strategic priority document
FDA grants accelerated approval to Beleodaq
SILVER SPRING, Md. — The Food and Drug Administration on Thursday announced approval for Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), which is a rare and fast-growing type of non-Hodgkin lymphoma (NHL).
The drug works by stopping enzymes that contribute to T-cells becoming cancerous. It's indicated for patients whose disease has returned post-treatment or those patients who did not respond to previous treatment.
“This is the third drug that has been approved since 2009 for the treatment of peripheral T-cell lymphoma,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Today’s approval expands the number of treatment options available to patients with serious and life-threatening diseases.”
In 2014, the National Cancer Institute estimates that 70,800 Americans will be diagnosed with NHL and 18,900 will die. PTCL makes up about 10% to 15% of NHLs in North America, the agency said.
Beleodaq is marketed by Spectrum Pharmaceuticals.